Navigation Links
LCA-Vision Announces CEO Resignation
Date:9/18/2009

CINCINNATI, Sept. 18 /PRNewswire-FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV), a leading provider of laser vision correction services under the LasikPlus(R) brand, announces that Steven C. Straus has resigned as Chief Executive Officer and a member of the company's board of directors effective September 25, 2009 to lead another healthcare company outside of the ophthalmology industry. Management of daily operations will be the responsibility of Chief Operating Officer David L. Thomas and Chief Financial Officer Michael Celebrezze, jointly reporting to the board of directors through non-Executive Chairman E. Anthony Woods.

"On behalf of the LCA-Vision board of directors, our surgeons and all employees, I would like to thank Steve for his service to our company and wish him well in his new endeavor," said Mr. Woods. "We are fortunate to have an excellent team in place companywide, and I am confident that our executives have the skills to advance our business plan and guide LCA-Vision through current macroeconomic challenges.

"The employees of LCA-Vision are fully committed to achieving success in the marketplace and, in turn, creating long-term sustainable shareholder value," he added. "Our strategic and operating plan continues to be built upon excellence in service and clinical outcomes, prudent expense management, innovative and effective marketing, advanced technology and an expanded and strengthened business model."

About LCA-Vision Inc./LasikPlus(R)

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus(R) brand, operates 71 LasikPlus(R) fixed-site laser vision correction centers in 31 states and 53 markets in the United States and a joint venture in Canada. Additional company information is available at www.lca-vision.com and www.lasikplus.com.

           Earning Trust Every Moment to Forge Lifetime Relationships.

    For Additional Information

    Company Contact:                Investor Relations Contact:
    Barb Kise                       Jody Cain
    LCA-Vision Inc.                 Lippert/Heilshorn & Associates
    513-792-9292                    310-691-7100


'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. LCA-Vision Names Michael J. Celebrezze CFO
2. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
4. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
5. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
6. Aethlon Medical, Inc. Announces Annual Meeting Results
7. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
8. Martek Announces Addition to Its Board of Directors
9. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
10. BVGH Announces New Board Chair
11. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for ... Breast Cancer Symposium. Using molecular test results from tumors with previously documented ...
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
(Date:12/2/2016)... YORK , Dec. 1, 2016   SurePure, ... photopurification, announced today that the Company has concluded an ... the right for a 90-day period to acquire units ... value of approximately USD 3.7 million.  ... agreement with Tamarack under which Tamarack will seek regulatory ...
(Date:11/30/2016)... 2016  GenomOncology today announced the appointment of Joshua ... Dr. Coleman will oversee clinical content development ... platform. The GenomOncology software suite empowers molecular pathologists with a ... clinical decision support, from quality control through reporting. ... , , ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):